Monitor Q4 2026 for Furoscix revenue trajectory, as management expects Q4 Furoscix revenue to exceed the first half of 2026 combined. Watch for updates on the global Phase 2 INFLO-2 trial for MNKD-201 and the $15M milestone payments from United Therapeutics anticipated in 2027.
Drugs in focus
MNKD drug pipeline →nintedanib DPI
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2 (enrolling)
- Time to market
- At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials and subsequent regulatory filings
- Next catalyst
- None dated
What to watchWatch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $3.90entry
- T+1 · 8d ago +7.44%α +5.07% · $4.19
- T+5 · 4d ago +5.90%α +3.30% · $4.13
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
MannKind reported Q3 2026 total revenue of $101.9M (+24% YoY), slightly below the $108.5M consensus, and GAAP EPS of -$0.07 vs consensus -$0.01. Furoscix revenue of $22.4M and the rapid adoption of Furoscix ReadyFlow (75% of shipments by late October) were highlights, but higher SG&A costs (up 111% YoY) drove a net loss of $23.2M vs a year-ago profit of $8.0M.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $101.9M, +24% YoY, below $108.5M consensus
- GAAP EPS -$0.07 vs consensus -$0.01 (miss)
- Non-GAAP adjusted net loss $3.6M, or -$0.01 per share
- Furoscix revenue $22.4M; Furoscix ReadyFlow launched mid-September, 75% of shipments by late October
- Afrezza revenue $19.3M, +5% YoY; pediatric launch driving 80% increase in new-to-brand prescriptions QoQ
- SG&A expenses $61.4M, +111% YoY, driven by Furoscix launch and pediatric Afrezza promotion
- Cash and investments $96.6M; closed $50M private placement in July 2026
- Positive Phase 1b INFLO-1 results for nintedanib DPI (MNKD-201); global Phase 2 underway
Financial Impact
Revenue miss of ~$6.6M vs consensus; net loss of $23.2M vs year-ago profit of $8.0M; SG&A more than doubled to $61.4M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Afrezza | $19.3M | +5.0% |
| Furoscix | $22.4M | Not reported |
| V-Go | $3.3M | -14.0% |
| Collaborations and services | $19.4M | -27.0% |
| Royalties | $37.5M | +12.0% |
Risk Factors
- Revenue missed consensus by ~6%, driven by lower collaboration revenue from UT
- SG&A expenses surged 111% YoY, pressuring profitability
- Net loss of $23.2M vs year-ago profit of $8.0M; cash burn may require additional financing
- Furoscix gross margin is lower than Afrezza, weighing on overall margins
- Dependence on United Therapeutics for royalty revenue and collaboration income
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397002 |
Track record
17 reports on MNKD
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Viewing Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers